Joincare Subsidiary Obtains Drug Registration Certificate for Banxia Baizhu Tianma Decoction Granules

CLS··Read original
2▲2 ▼0Impact / 5
Summary · why it matters

Joincare announced that its controlled subsidiary, Livzon Group's subsidiary Sichuan Guangda Pharmaceutical, has received a Drug Registration Certificate issued by the National Medical Products Administration, approving the market launch of Banxia Baizhu Tianma Decoction Granules. This drug is a Category 3.1 new traditional Chinese medicine, the company's first approved Category 3.1 new TCM drug, which will further enrich the company's product pipeline. As of the announcement date, the cumulative R&D investment for this drug was approximately 5.01 million yuan.

Impact on assets 2

Others▲ · 2 stocks

Off-coverage companies 1

四川光大制药有限公司Private▲ Positive
Technologyrelevance

Directly received the drug registration certificate for Banxia Baizhu Tianma Decoction Granules.

© 2026 MarketIVNews